Core Viewpoint - The company reported strong revenue and profit growth in the first half of 2025, indicating robust performance across various product lines and channels [1][2]. Revenue Performance - In H1 2025, the company achieved revenue of 3.113 billion yuan, representing a year-on-year increase of 22.52% [1]. - Revenue breakdown by product category: - Efficacy skincare products: 2.410 billion yuan, accounting for 77.4%, with a growth of 24.2% - Medical dressings: 693 million yuan, accounting for 22.3%, with a growth of 17.1% - Health food and others: 10 million yuan, accounting for 0.3%, with a growth of 16.3% [1]. - Revenue breakdown by sales channel: - Direct sales: 2.325 billion yuan, accounting for 74.7%, with a growth of 26.5% - Distribution: 787 million yuan, accounting for 25.3%, with a growth of 12.1% [1]. Profitability Metrics - The company reported a gross margin of 81.68%, down by 0.72 percentage points, and a net profit margin of 37.98%, also down by 0.72 percentage points [2]. - The decline in gross margin was attributed to product category expansion, while supply chain cost optimization mitigated some of the downward trend [2]. Cost Management - The company's expense ratio decreased to 37.99%, down by 1.63 percentage points, with a sales expense ratio of 34.01%, down by 1.10 percentage points [2]. - R&D expense ratio decreased to 1.32%, down by 0.59 percentage points, due to the transition of some R&D projects to commercialization and reduced share-based compensation [2]. R&D and Product Development - The company is enhancing its R&D capabilities and expanding its product matrix, which is expected to support long-term growth [2]. - New product launches, such as the collagen stick 2.0 and collagen mask 3.0, have received positive consumer feedback, indicating strong product vitality [2]. Future Outlook - The company is expected to achieve revenues of 7.056 billion yuan, 8.790 billion yuan, and 10.568 billion yuan from 2025 to 2027, with net profits of 2.538 billion yuan, 3.189 billion yuan, and 3.867 billion yuan respectively [3]. - The company maintains a strong position in the collagen protein sector, with anticipated improvements in industry standing and penetration rates [3].
巨子生物(02367.HK)：业绩维持稳增 多元化矩阵构筑广阔空间